cd19/cd20 bispecific car-t cells
Cell therapyexperimental
Clinical trial activity
11 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT04156178)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06503094 | Phase 1/Phase 2 (Phase 2) | Jan 14, 2024 | Central South University, Government of China, Huazhong University of Science and Technology, Jingzhou Central Hospital, People's Hospital Of Yichang, Shiyan People's Hospital, Southern Medical University |
| NCT05421663 | Phase 1 | Aug 9, 2022 | Cellular Biomedicine Group Ltd., City of Hope National Medical Center |
| NCT04697290 | Early Phase 1 (Phase 1) | Mar 10, 2021 | China Immunotech, Tsinghua University |
| NCT04696432 | Phase 1 | Sep 21, 2020 | Tianjin Medical University |
| NCT04655677 | Phase 1 | Aug 25, 2020 | Chinese Academy of Medical Sciences |
| NCT04693676 | Phase 1 | Jul 10, 2020 | Zhejiang University |
| NCT04260945 | Phase 1 | Feb 10, 2020 | China Immunotech, Ludaopei Hospital |
| NCT04260932 | Phase 1 | Feb 10, 2020 | China Immunotech, Ludaopei Hospital |
| NCT04317885 | Phase 1 | Oct 14, 2019 | Huazhong University of Science and Technology |
| NCT03881761 | Phase 1 | Feb 1, 2019 | Henan Hualong Biotechnology Company, Henan Medical University |
| NCT04156178 | Early Phase 1 (Phase 1) | Aug 1, 2018 | iCell Gene Therapeutics, Peking University, People's Liberation Army of China |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (20)
20 organizations
Page 1 / 1